Advancing targeted protein degradation via multiomics profiling and artificial intelligence

M Duran-Frigola, M Cigler… - Journal of the American …, 2023 - ACS Publications
Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …
被引用次数：17 相关文章
[HTML] nih.gov

[HTML][HTML] Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence

M Duran-Frigola, M Cigler, GE Winter - Journal of the American …, 2023 - ncbi.nlm.nih.gov
Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence

M Duran-Frigola, M Cigler… - Journal of the American …, 2023 - pubmed.ncbi.nlm.nih.gov
Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence.

M Duran-Frigola, M Cigler, GE Winter - Journal of the American …, 2023 - europepmc.org
Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence.

M Duran-Frigola, M Cigler, GE Winter - Journal of the American …, 2023 - europepmc.org
Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …